Literature DB >> 6258079

Functional reactivation of the deafferented neostriatum by nigral transplants.

A Björklund, U Stenevi, S B Dunnett, S D Iversen.   

Abstract

Functional deficits following brain lesions can be due not only to the disruption of conduction in specific input and output pathways passing through the site of injury, but also to the loss of important regulatory systems controlling the functional state of neuronal circuitries in areas distant from the lesion. For example, the behavioural disturbances that result from lesions of the nigrostriatal dopamine (DA) pathways can be reversed by administration of dopamine receptor-activating drugs, such as L-dopa or apomorphine. This suggests that the lesioned dopaminergic system, rather than conveying specific input and output signals, is normally acting on neuronal machineries whose activity levels are set by the activity at the dopaminergic synapses. Thus the neurological deficits resulting from these lesions are due to functional inactivation of otherwise intact neostriatal circuitries. Previous studies have shown that intracerebral transplants of embryonic substantia nigra can compensate for drug-induced as well as spontaneous asymmetric motor behaviour (expressed as a tendency to move in circles towards the lesioned side), whereas the sensorimotor asymmetry, which is pronounced in rats with a unilateral lesion of the nigrostriatal DA pathway, was unaffected by the transplant. We report here that restoration of striatal dopaminergic neurotransmission by nigral transplants in animals with bilateral, complete lesions of the nigral transplants in animals with bilateral, complete lesions of the nigrostriatal DA pathways can reinstate not only certain aspects of spontaneous motor behavior, but also sensorimotor orientation and sensory attention on the side of the body contralateral to the graft.

Entities:  

Mesh:

Year:  1981        PMID: 6258079     DOI: 10.1038/289497a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  24 in total

1.  Restorative plasticity of dopamine neuronal transplants depends on the degree of hemispheric dominance.

Authors:  G Nikkhah; G Falkenstein; C Rosenthal
Journal:  J Neurosci       Date:  2001-08-15       Impact factor: 6.167

Review 2.  Emerging regenerative medicine and tissue engineering strategies for Parkinson's disease.

Authors:  James P Harris; Justin C Burrell; Laura A Struzyna; H Isaac Chen; Mijail D Serruya; John A Wolf; John E Duda; D Kacy Cullen
Journal:  NPJ Parkinsons Dis       Date:  2020-01-08

3.  Profile of Anders Bjorklund. Interview by Beth Azar.

Authors:  Anders Bjorklund
Journal:  Proc Natl Acad Sci U S A       Date:  2012-07-16       Impact factor: 11.205

4.  Degeneration and graft-induced restoration of dopamine innervation in the weaver mouse neostriatum: a quantitative radioautographic study of [3H]dopamine uptake.

Authors:  G Doucet; P Brundin; S Seth; Y Murata; R E Strecker; L C Triarhou; B Ghetti; A Björklund
Journal:  Exp Brain Res       Date:  1989       Impact factor: 1.972

5.  Synaptic input and local output of dopaminergic neurons in grafts that functionally reinnervate the host neostriatum.

Authors:  J P Bolam; T F Freund; A Björklund; S B Dunnett; A D Smith
Journal:  Exp Brain Res       Date:  1987       Impact factor: 1.972

6.  Immunocytochemical study of PC12 cells grafted to the brain of immature rats.

Authors:  C B Jaeger
Journal:  Exp Brain Res       Date:  1985       Impact factor: 1.972

Review 7.  Transplantation of fetal cells and tissue: an overview.

Authors:  A Fine
Journal:  CMAJ       Date:  1994-11-01       Impact factor: 8.262

8.  Neuroprotective effects of alpha-dihydroergocryptine against damages in the substantia nigra caused by severe treatment with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.

Authors:  G Bernocchi; G Gerzeli; E Scherini; C Vignola
Journal:  Acta Neuropathol       Date:  1993       Impact factor: 17.088

9.  The A9 dopamine neuron component in grafts of ventral mesencephalon is an important determinant for recovery of motor function in a rat model of Parkinson's disease.

Authors:  Shane Grealish; Marie E Jönsson; Meng Li; Deniz Kirik; Anders Björklund; Lachlan H Thompson
Journal:  Brain       Date:  2010-01-31       Impact factor: 13.501

10.  Targeting the progression of Parkinson's disease.

Authors:  J L George; S Mok; D Moses; S Wilkins; A I Bush; R A Cherny; D I Finkelstein
Journal:  Curr Neuropharmacol       Date:  2009-03       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.